Edwards Lifesciences (EW)’s Chairman & CEO Michael Mussallem Sold 32,800 Shares; KOMAX HOLDING AG DIERIKON NAMEN-AKT SHAR (KMAAF) Sellers Decreased By 60.81% Their Shorts

Edwards Lifesciences Corporation (NYSE:EW) Logo

KOMAX HOLDING AG DIERIKON NAMEN-AKT SHAR (OTCMKTS:KMAAF) had a decrease of 60.81% in short interest. KMAAF’s SI was 2,900 shares in May as released by FINRA. Its down 60.81% from 7,400 shares previously. With 100 avg volume, 29 days are for KOMAX HOLDING AG DIERIKON NAMEN-AKT SHAR (OTCMKTS:KMAAF)’s short sellers to cover KMAAF’s short positions. The SI to KOMAX HOLDING AG DIERIKON NAMEN-AKT SHAR’s float is 0.08%. It closed at $311 lastly. It is down 0.00% since May 3, 2017 and is . It has underperformed by 11.55% the S&P500.

Komax Holding AG develops, produces, and sells capital goods for precision engineering, electronics, and information technology in the areas of wire processing, and automated production and assembly. The company has market cap of $1.04 billion. The firm offers electrical, rotary, and coaxial wire strippers, as well as rotary jacket strippers; wire crimpers for semiautomatic machines; cutting and stripping machines; crimp to crimp wire processing machines for processing single conductors and double-crimp connections; wire twisting machines; and harness machines for block loading and wire harness manufacturing. It has a 27.13 P/E ratio. It also provides wire handling machines for preliminary wire processing; automatic wire processing machines; process modules for economical production; monitoring modules; software solutions for automatic crimping machines; a range of accessories; and test systems.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $27.76 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 48.77 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

After the disclosing of a report filled with Washington-based SEC; a large and important insider sale became apparent. The Chairman & CEO of Edwards Lifesciences Corp, Michael Mussallem; made a significant trade in the open market by unloading 32,800 shares at an avg stock price per share of $128.5 of the Pinksheet-listed company having a total value of $4,213,519 U.S Dollars. The prospect that this deal remains unnoticed are nil on account of the substantial amount of money involved. Presently, Michael Mussallem owns 863,357 shares which make up roughly 0.41% of the Company’s market capitalization.

The stock decreased 0.69% or $0.91 during the last trading session, reaching $131.68. About 1.60 million shares traded or 5.14% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since May 3, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 21 have Buy rating, 1 Sell and 6 Hold. Therefore 75% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $135.09’s average target is 2.59% above currents $131.68 stock price. Edwards Lifesciences Corp had 112 analyst reports since July 30, 2015 according to SRatingsIntel. Barclays Capital maintained Edwards Lifesciences Corporation (NYSE:EW) on Thursday, April 7 with “Equal-Weight” rating. The stock has “Overweight” rating by Morgan Stanley on Wednesday, July 27. The rating was upgraded by Northland Capital to “Outperform” on Tuesday, November 8. As per Friday, December 8, the company rating was maintained by Cowen & Co. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Buy” rating by Jefferies on Tuesday, September 5. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. The company was maintained on Monday, May 23 by Canaccord Genuity. Guggenheim maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Friday, February 2. Guggenheim has “Buy” rating and $162.0 target. The rating was maintained by Barclays Capital with “Equal-Weight” on Wednesday, October 25. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Hold” rating by Deutsche Bank on Thursday, October 26.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart